GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mymetics Corp (OTCPK:MYMX) » Definitions » Operating Margin %

Mymetics (Mymetics) Operating Margin % : 0.00% (As of Sep. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Mymetics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Mymetics's Operating Income for the three months ended in Sep. 2023 was $-0.41 Mil. Mymetics's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Mymetics's Operating Margin % for the quarter that ended in Sep. 2023 was 0.00%.

Warning Sign:

Mymetics Corp operating margin has been in a 5-year decline. The average rate of decline per year is -154.1%.

The historical rank and industry rank for Mymetics's Operating Margin % or its related term are showing as below:

MYMX' s Operating Margin % Range Over the Past 10 Years
Min: -62133.33   Med: -1076.3   Max: 52.82
Current: -43500


MYMX's Operating Margin % is not ranked
in the Biotechnology industry.
Industry Median: -169.17 vs MYMX: -43500.00

Mymetics's 5-Year Average Operating Margin % Growth Rate was -154.10% per year.

Mymetics's Operating Income for the three months ended in Sep. 2023 was $-0.41 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.61 Mil.

Warning Sign:

Mymetics Corp has never been profitable in the past 3 years. It lost money every year.


Mymetics Operating Margin % Historical Data

The historical data trend for Mymetics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mymetics Operating Margin % Chart

Mymetics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,032.94 -1,247.15 -4,453.49 -62,133.33 -61,633.33

Mymetics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -17,100.00 -42,866.67 - -

Competitive Comparison of Mymetics's Operating Margin %

For the Biotechnology subindustry, Mymetics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mymetics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mymetics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Mymetics's Operating Margin % falls into.



Mymetics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Mymetics's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-1.849 / 0.003
=-61,633.33 %

Mymetics's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=-0.407 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mymetics  (OTCPK:MYMX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Mymetics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Mymetics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mymetics (Mymetics) Business Description

Traded in Other Exchanges
N/A
Address
c/o Mymetics SA, Route de la Corniche 4, Biopole Center, Epalinges, CHE, CH-1066
Mymetics Corp is a vaccine company and is focused on the research and development of next-generation vaccines for infectious and life-disabling diseases. Its vaccine candidates in the pipeline include HIV-1/AIDS, malaria, and Covid-19, and intranasal influenza, RSV, Chikungunyaand HSV vaccine candidate programs.
Executives
Marcel B. Ruegg director C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Kempers Ronald Hugo Gerard officer: President, CEO, CFO ES GRANDS CHAMPS 12, DULLY V8 1195
Christopher S Henney director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Grant Pickering director, officer: President and CEO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Ulrich Burkhard director C/O MYMETICS CORPORATION, ROUTE DE LA CORNICHE 4 1066, EPALINGES V8 NA
Jacques Francois Martin officer: CEO 40 QUAI FULCHIRON, LYON I0 69005
Antonius Johannes Stegmann officer: CSO KONINGIN EMMAPLANTSOEN 6, RIJNSBURG P7 2231TZ
Ernest M Stern director 815 CONNECTICUT AVE, NW, SUITE 500, SEYFARTH SHAW LLP, WASHINGTON DC 20006
Thomas Staehelin director POSTFACH 2879, FROMER, SCHULTHEISS & STAEHELIN, BASEL V8 CH-4002
Sylvain Fleury officer: CSO CHEMIN DE VERDONNET 9, LAUSANNE V8 1010
Round Enterprises, Ltd. 10 percent owner C/O BACHMANN TRUST COMPANY LIMITED, FRANCES HOUSE, SIR WILLIAM PLACE, ST. PETER PORT X0 GY1 4EA
Mfc Bancorp Ltd 10 percent owner ROOM 2103 SHANGHAI MART TOWER, 2299 YAN AN ROAD WEST, CHANGNING DISTRICT, SHANGHAI F4 200336
Christian Rochet director, officer: CEO 14, RUE DE LA COLOMBIERE, NYON V8 1260
Robert Zimmer director, officer: vp corp development
Ernst Lubke director, officer: CFO 39, ROUTE D'ARZIER, ARZIER V8 CH-1273